When pharmaceutical giants SmithKline Beecham and Glaxo Wellcome officially complete their merger on August 21 the two companies will have committed to spend nearly £112m (€179.2m) on advisory fees.

The fees, which neither company will break down for the public, will, according to a spokesperson at SmithKline Beecham, go to 12 different firms.